Literature DB >> 15385942

Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-gamma1 in acute myeloid leukemia cells.

R B Walter, B W Raden, J Thompson, D A Flowers, H-P Kiem, I D Bernstein, M L Linenberger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15385942     DOI： 10.1038/sj.leu.2403461

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

1.  Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.

Authors:  George S Laszlo; Chelsea J Gudgeon; Kimberly H Harrington; Justine Dell'Aringa; Kathryn J Newhall; Gary D Means; Angus M Sinclair; Roman Kischel; Stanley R Frankel; Roland B Walter
Journal:  Blood       Date:  2013-12-05       Impact factor: 22.113

2.  PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism.

Authors:  Roland B Walter; Jason L Pirga; Michelle R Cronk; Sasha Mayer; Frederick R Appelbaum; Deborah E Banker
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

Review 3.  Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.

Authors:  Andrew J Cowan; George S Laszlo; Elihu H Estey; Roland B Walter
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

Review 4.  Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.

Authors:  Laurène Fenwarth; Elise Fournier; Meyling Cheok; Thomas Boyer; Fanny Gonzales; Sylvie Castaigne; Nicolas Boissel; Juliette Lambert; Hervé Dombret; Claude Preudhomme; Nicolas Duployez
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.